RT Book, Section
A1 Kiser, Jennifer J.
A2 Brunton, Laurence L.
A2 Knollmann, Björn C.
SR Print(0)
ID 1193240212
T1 Treatment of Viral Hepatitis (HBV/HCV)
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264258079
LK hemonc.mhmedical.com/content.aspx?aid=1193240212
RD 2024/04/19
AB Hepatitis  viruses  cause  inflammation  and  necrosis  of  the  liver.  Hepatitis  A  and  E,  which  are  transmitted  via  the  fecal-oral  route,  are  typically  self-limiting,  although  a  small  percentage  (1%–2%)  of  those  infected  will  develop  fulminant  hepatic  failure.  Hepatitis  B  virus  (HBV),  hepatitis  C  virus  (HCV),  and  hepatitis  D  viruses,  however,  are  transmitted  parenterally.  Hepatitis  B  and  C  may  or  may  not  cause  symptoms  of  acute  infection,  but  both  may  progress  to  chronic  infection.  Individuals  with  chronic  hepatitis  B  or  C  infection  are  at  risk  for  cirrhosis,  liver  failure,  and  hepatocellular  carcinoma.  There  are  two  notable  differences  between  HBV  and  HCV.  First,  HBV  is  a  vaccine-preventable  illness,  whereas  there  is  no  vaccine  available  to  prevent  HCV.  Second,  HCV  can  be  cured  with  effective  treatment,  whereas  the  current  treatments  for  HBV  are  not  completely  curative.  The  hepatitis  D  virus  is  defective  and  requires  the  presence  of  the  HBV  to  propagate.  Individuals  coinfected  with  hepatitis  B  and  D  are  at  greater  risk  for  cirrhosis  and  hepatocellular  carcinoma  compared  with  individuals  with  only  hepatitis  B  infection,  but  fortunately,  only  about  5%  of  individuals  with  HBV  are  coinfected  with  hepatitis  D.